Susan Montgomery / Shutterstock.com
15 February 2016Big Pharma
Eli Lilly loses latest round of Alimta patent battle
Eli Lilly has lost the latest round of its patent battle with Allergan centring on the lung cancer drug Alimta (pemetrexed disodium).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
29 June 2015 The English Court of Appeal has ruled in favour of Eli Lilly, finding that a patent covering its blockbuster lung drug Alimta would be infringed by a product proposed by Actavis, now Allergan.
Big Pharma
24 March 2016 The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.
Editor's picks
Editor's picks
Americas
29 June 2015 The English Court of Appeal has ruled in favour of Eli Lilly, finding that a patent covering its blockbuster lung drug Alimta would be infringed by a product proposed by Actavis, now Allergan.
Big Pharma
24 March 2016 The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.
Americas
29 June 2015 The English Court of Appeal has ruled in favour of Eli Lilly, finding that a patent covering its blockbuster lung drug Alimta would be infringed by a product proposed by Actavis, now Allergan.
Big Pharma
24 March 2016 The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta.